OCUL Stock Overview
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocular Therapeutix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.93 |
| 52 Week High | US$11.31 |
| 52 Week Low | US$2.00 |
| Beta | 1.32 |
| 1 Month Change | -29.74% |
| 3 Month Change | 18.60% |
| 1 Year Change | -9.47% |
| 3 Year Change | -62.35% |
| 5 Year Change | 64.72% |
| Change since IPO | -54.90% |
Recent News & Updates
Recent updates
Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates
May 13Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
May 10Shareholder Returns
| OCUL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 25.1% | 1.6% | 3.3% |
| 1Y | -9.5% | 12.6% | 25.8% |
Return vs Industry: OCUL underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: OCUL underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| OCUL volatility | |
|---|---|
| OCUL Average Weekly Movement | 15.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OCUL's share price has been volatile over the past 3 months.
Volatility Over Time: OCUL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 267 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix, Inc. Fundamentals Summary
| OCUL fundamental statistics | |
|---|---|
| Market cap | US$917.53m |
| Earnings (TTM) | -US$80.74m |
| Revenue (TTM) | US$58.44m |
15.7x
P/S Ratio-11.4x
P/E RatioIs OCUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCUL income statement (TTM) | |
|---|---|
| Revenue | US$58.44m |
| Cost of Revenue | US$66.34m |
| Gross Profit | -US$7.89m |
| Other Expenses | US$72.84m |
| Earnings | -US$80.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -13.51% |
| Net Profit Margin | -138.14% |
| Debt/Equity Ratio | 82.2% |
How did OCUL perform over the long term?
See historical performance and comparison